Functional Diagnostics in Massachusetts

Commonwealth Diagnostics International (CDI) is a CLIA-certified clinical laboratory and diagnostic solutions provider specializing in hydrogen and methane breath testing for functional gastrointestinal disorders. CDI manufactures and distributes non-invasive, at-home breath test kits for the diagnosis of small intestinal bacterial overgrowth (SIBO), intestinal methanogen overgrowth (IMO), and carbohydrate malabsorption disorders (fructose, lactose, and sucrose malabsorption) in both adult and pediatric populations. The company operates proprietary gas chromatography instrumentation for test analysis and offers MyGI Gateway, a cloud-based digital platform for centralized management of patient orders, data, and results reporting. CDI delivers test results within one business day and maintains ISO 13485 certification, FDA registration, CE marking, and SAM.gov registration. The company serves gastroenterology practices, functional medicine providers, naturopathic doctors, and direct-to-consumer patients. CDI emphasizes clinically validated testing methods, peer-reviewed evidence, rapid turnaround, insurance coverage coordination (Medicare and commercial), and comprehensive provider and patient support resources including educational content, clinical guidelines, and billing assistance. The laboratory is located in Salem, Massachusetts.

Mauna Kea Technologies is a global medical device company specializing in Confocal Laser Endomicroscopy (CLE) and in vivo cellular imaging. The flagship Cellvizio® platform delivers real-time histological visualization during endoscopy procedures across gastroenterology, pulmonology, urology, and neurosurgery, enabling physicians to accelerate diagnosis, inform treatment decisions, and guide surgical interventions with cellular-level precision. FDA-cleared and CE-marked, Cellvizio has been used in over 100,000 patient procedures worldwide. The company partners with industry leaders including Johnson & Johnson and Telix Pharmaceuticals to expand therapeutic applications in precision medicine, cancer detection, and early intervention across multiple clinical specialties.

Medical Monofilament manufactures sensory testing monofilaments for diabetic foot ulceration and amputation prevention since 1999. The company holds FDA 510(k) clearance and operates as the only automated manufacturer of precision monofilaments in the U.S., utilizing a proprietary automated manufacturing process that ensures consistent quality and calibration. All products and components are manufactured domestically. Medical Monofilament is women-owned and operated, serving healthcare providers and diabetic care programs with affordable, high-quality diagnostic tools for neuropathy assessment and patient education in diabetes management.

Momentum Health Inc. develops Momentum Spine, a radiation-free 3D digital spine monitoring platform that uses smartphone video capture to create clinical-grade 3D spine scans and AI-powered analytics. The platform enables remote monitoring of complex spine conditions—particularly pediatric scoliosis (AIS) and adult spinal deformity—without requiring in-person X-rays or imaging center visits. The system employs deep-learning models to predict Cobb Angle (mean absolute error ~5–6°, comparable to inter-observer radiologist variation), track spinal asymmetry, assess brace compliance, analyze dynamic gait and posture metrics, and monitor whole-body sagittal alignment. Patients perform 45-second smartphone scans at home; clinicians access a secure web dashboard for real-time remote monitoring, triage, and data-driven intervention planning. Momentum Spine integrates into clinical workflows and supports Remote Therapeutic Monitoring (RTM) billing models. The company holds FDA 510(k) clearance (K232023, product code LDK) for the US market and Canadian Medical Device Establishment License (MDEL) clearance. The platform is SOC 2 Type 2 certified, HIPAA and PIPEDA compliant, and maintains ISO 13485 quality certification. Target markets include spine centers, hospital networks, pediatric orthopedic clinics, and research institutions. The company is based in Montreal, Canada, and serves leading healthcare systems including UCSF, NYP Och Spine, Cedars-Sinai, and Children's Hospital Los Angeles.

Cassini Technologies B.V. is an ophthalmic diagnostic and surgical planning solutions company headquartered in The Netherlands with US operations in Massachusetts and Florida. The company specializes in corneal diagnostics and intraoperative guidance systems for cataract and refractive surgery. Their core product line includes the Cassini Ambient, a corneal topography and biometry device that captures anterior and posterior corneal data using multicolor visible LEDs combined with infrared illumination, enabling highly repeatable measurements for toric intraocular lens (IOL) planning and astigmatism management. The Cassini Connect OR platform integrates preoperative diagnostics with intraoperative guidance, presenting surgical reference information in the operating room and supporting workflow continuity. The system features iris registration technology for automated cyclotorsion compensation and direct integration with femtosecond laser-assisted cataract surgery (FLACS) platforms including CATALYS and LENSAR, streamlining data transfer and reducing transcription errors. Cassini's solutions are designed to improve surgical accuracy and predictability, particularly for toric IOL placement and astigmatism correction. The company works with cataract surgeons, refractive specialists, and surgical centers across the US and internationally, emphasizing user-friendly operation, fast image acquisition, and open platform architecture enabling partnerships with major ophthalmic equipment manufacturers including Leica Microsystems. Clinical evidence demonstrates improved outcomes in toric lens volume, reduced prediction error in IOL power calculations, and enhanced astigmatic outcomes comparable to prevalent biometry combined with intraoperative aberrometry.

BrainSpec, Inc develops a cloud-based software platform for Magnetic Resonance Spectroscopy (MRS) analysis. The platform provides non-invasive 'virtual biopsy' capability by measuring brain metabolite concentrations at precision levels 10,000 times lower than conventional MRI. BrainSpec Core™ combines a linear combinations model post-processing backend with a user-friendly web interface for clinicians and researchers. The platform supports cross-vendor MRI compatibility, enables precision metabolite measurement, and provides automated reporting with cloud-based processing to ensure access to cutting-edge analytical algorithms. Applications include assessment of brain tumors, Alzheimer's disease, Multiple Sclerosis, and other neurological conditions. The company has developed proprietary reference databases of normal and diseased brain chemistry to streamline MRS interpretation to clinical utility standards comparable to routine blood testing. The platform is currently in the pre-market stage with FDA clearance pending. The company is accepting a limited number of pilot research sites. Over 28,000 publications document clinical applications of MRS technology.

Linus Health is a digital health company that develops AI-enabled cognitive assessment platforms for early detection and management of cognitive impairment and dementia. The company provides scientifically-validated digital cognitive testing solutions that integrate long-trusted neuropsychological assessments with advanced analytics to deliver actionable clinical insights. Linus Health's platform serves two primary market segments: healthcare delivery (primary care practices, medical centers, specialty neurology) and life sciences (clinical trials, research studies). The technology originated from 8+ years of R&D performed at MIT and Lahey Medical Center. The platform has been validated in over 150 peer-reviewed publications across journals including Neurology, Journal of Alzheimer's Disease, and Neuropsychologia, demonstrating sensitivity in detecting subtle cognitive impairment and associations with Alzheimer's biomarkers. The company targets the significant gap in cognitive care capacity—projected neurologist shortages of 19% by 2025—and the critical window for intervention, as Alzheimer's pathology can present 15-20 years before overt symptoms. Linus Health's digital assessment approach makes cognitive testing more accessible, practical, and efficient compared to traditional in-clinic methods. The platform is designed for integration across care settings and supports earlier detection workflows aligned with emerging biomarker-driven treatment paradigms. The company has received recognition including TIME Magazine Best Inventions and Fast Company Innovation by Design awards.

Lucid Diagnostics develops and commercializes the EsoGuard DNA test, a non-invasive next-generation sequencing diagnostic designed to detect esophageal precancer (Barrett's esophagus) in office-based settings without endoscopy. The company targets high-risk populations, including patients with chronic reflux symptoms and occupational cohorts such as firefighters (who have a 62% increased risk of esophageal cancer). EsoGuard enables early detection of precancerous changes, allowing clinicians to intervene before disease progression to esophageal adenocarcinoma. The test leverages targeted NGS technology to identify molecular markers of Barrett's esophagus and dysplasia. Lucid partners with gastroenterology practices, primary care clinics, and occupational health programs to integrate the test into routine screening workflows. The company serves patients and healthcare systems across the United States. Regulatory status and specific FDA clearance details are not explicitly stated in available content, though the product is actively marketed and endorsed by board-certified gastroenterologists and surgeons at major medical institutions. Manufacturing and laboratory processing capabilities are referenced through clinical partnerships and patient testimonials. The company is publicly traded and provides investor updates on financial and operational performance.

binx health is a molecular diagnostics company specializing in point-of-care testing platforms for sexually transmitted infections and other infectious diseases. The company's flagship product, binx io, is an FDA-cleared, CLIA-waived molecular platform enabling single-visit diagnosis and treatment of chlamydia and gonorrhea infections with 30-minute time-to-results. binx io delivers rapid molecular diagnostics in clinical settings including urgent care, primary care clinics, sexual health clinics, and community health centers, supporting both male and female patients. The platform has established reimbursement pathways and is distributed nationally through partnerships with major healthcare distributors including Cardinal Health and Afaxys. binx health also developed binx everywhere, an at-home self-collection testing platform for STI and HPV screening. The company operates a reagent rental model and supplies molecular reagents to decentralized testing locations. binx health's point-of-care diagnostic solutions are designed to expand equitable access to healthcare, reduce traditional barriers to care, and enable rapid diagnosis-and-treatment workflows in community settings. The company has received regulatory clearance, strategic partnerships with healthcare systems, nonprofit organizations, and public health agencies, and recognition as a digital health innovator.

Boston Easy Biotech Inc manufactures and distributes rapid diagnostic testing solutions under the Famwell™ brand. The company focuses on point-of-care and over-the-counter (OTC) rapid testing products designed for both clinical laboratory and at-home consumer use. Product lines include respiratory testing, fertility testing, and drug-of-abuse testing. The company targets clinical laboratories, pharmacy chains, retail channels, and consumers seeking fast, reliable diagnostic results. Boston Easy Biotech exhibits at major industry conferences including ADLM 2026 (American Association for Clinical Laboratory Science) and NACDS Total Store Expo 2026, positioning itself within the evolving diagnostics landscape and OTC consumer health segments. All products emphasize ease of use and reliability. The company is based in Andover, Massachusetts, and operates customer order fulfillment and support services.

PAVmed, Inc. is a commercial-stage, diversified medical technology company focused on developing innovative diagnostics and digital health solutions. The company operates through two primary business units: Lucid Diagnostics and Veris Health. Lucid Diagnostics commercializes EsoGuard®, the first and only diagnostic test for detecting esophageal precancer and cancer, delivered via both traditional clinical settings and mobile test units. Veris Health develops a digital health platform and connected health devices for enhanced personalized cancer care through remote patient monitoring. PAVmed operates a shared-services business model that enables economies of scale across its subsidiaries. The company demonstrates clinical commitment through partnerships including participation in CancerX, a public-private partnership co-hosted by Moffitt Cancer Center and the Digital Medicine Society. Products are positioned for healthcare systems, clinicians, and patients across device, diagnostics, and digital health sectors. Recent press activity indicates ongoing expansion of medical device portfolio and continued commercialization efforts. The company maintains investor relations presence and actively engages in disease awareness initiatives such as firefighter screening programs for esophageal precancer detection.

Elucid Bioimaging develops FDA-cleared cardiovascular imaging analytics software specializing in quantitative plaque assessment from coronary CT angiography (CCTA). The company's flagship product, PlaqueIQ™, employs CT Virtual Histology™ technology to characterize arterial plaque composition non-invasively, leveraging algorithms trained and validated against ground-truth histopathology. PlaqueIQ quantifies and classifies plaque morphology into calcified, non-calcified matrix, and lipid-rich necrotic core (LRNC) components, delivering patient-, vessel-, and lesion-level analysis with high correlation to ex vivo histology (r=0.87–0.99 across plaque types). The software integrates into clinical PACS workflows via DICOM-wrapped PDFs and interactive browser-based reports, enabling physicians to assess coronary and carotid atherosclerosis risk and guide medical versus interventional treatment decisions. Elucid holds FDA 510(k) clearance (K183012, December 2018) and has achieved Category I CPT coding and broad CMS reimbursement as of January 2026. The company also develops FFRCT (fractional flow reserve CT) technology under regulatory pathway. Served markets include cardiology, interventional cardiology, radiology, and cardiovascular research. Clinical validation includes partnership with CVPath Institute and peer-reviewed publications in major cardiovascular literature.